This database contains 523 studies, archived under the term: "Alzheimer’s Disease"
Click here to filter this large number of results.
Orengedoku-to augmentation in cases showing partial response to yokukan-san treatment: A case report and literature review of the evidence for use of these Kampo herbal formulae
Okamoto, Hideki,
Chino, Atsushi,
Hirasaki, Yoshiro,
Ueda, Keigo,
Iyo, Masaomi,
Namiki, Takao
Background: Yokukan-san, a Japanese traditional herbal (Kampo) prescription, has recently gathered increasing attention due to accumulating reports showing its remarkable efficacy in treating a wide variety of diseases refractory to conventional medicine as well as the behavioral and psychological symptoms of dementia. As yokukan-san has become broadly integrated with conventional medicine, augmentation therapy with other […]
Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer’s disease
Okahara, Kazunori,
Ishida, Yasushi,
Hayashi, Yoshihito,
Inoue, Teruhiko,
Tsuruta, Kazuhito,
Takeuchi, Kouzou,
Yoshimuta, Hirofumi,
Kiue, Kouichirou,
Ninomiya, Yoshimasa,
Kawano, Jiro,
Yoshida, Kensei,
Noda, Shouji,
Tomita, Seiichiro,
Fujimoto, Masumi,
Hosomi, Jun,
Mitsuyama, Yoshio
Yokukansan (YKS) is used frequently against behavioral and psychological symptoms of dementia (BPSD) together with donepezil in patients with Alzheimer’s disease (AD). Here, we investigated the efficacy and safety of YKS in patients with AD in a non-blinded, randomized, parallel-group comparison study. Patients who had at least one symptom score of four or more on […]
The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer’s disease
Ohnishi, Takashi,
Sakiyama, Yojiro,
Okuri, Yuichi,
Kimura, Yuji,
Sugiyama, Nami,
Saito, Takayuki,
Takahashi, Masayoshi,
Kobayashi, Takumi
The prediction of efficacy in long-term treatment of acetylcholinesterase inhibitors (AChEIs) is a major clinical issue, although no consistently strong predictive factors have emerged thus far. The present analyses aimed to identify factors for predicting long-term outcome of galantamine treatment. Analyses were conducted with data from a 24 weeks randomized, double-blind, placebo controlled trial to […]
18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias
O'Brien, J. T.,
Firbank, M. J.,
Davison, C.,
Barnett, N.,
Bamford, C.,
Donaldson, C.,
Olsen, K.,
Herholz, K.,
Williams, D.,
Lloyd, J.
Unlabelled: Brain imaging with glucose ((18)F-FDG) PET or blood flow (hexamethylpropyleneamine oxime) SPECT is widely used for the differential diagnosis of dementia, though direct comparisons to clearly establish superiority of one method have not been undertaken.; Methods: Subjects with Alzheimer disease (AD; n = 38) and dementia with Lewy bodies (DLB; n = 30) and […]
The impact of supplemental macular carotenoids in Alzheimer’s disease: A randomized clinical trial
Nolan, John M.,
Loskutova, Ekaterina,
Howard, Alan,
Mulcahy, Riona,
Moran, Rachel,
Stack, Jim,
Bolger, Maggie,
Coen, Robert F.,
Dennison, Jessica,
Akuffo, Kwadwo Owusu,
Owens, Niamh,
Power, Rebecca,
Thurnham, David,
Beatty, Stephen
Background: Patients with Alzheimer’s disease (AD) exhibit significantly less macular pigment (MP) and poorer vision when compared to control subjects. Objective: To investigate supplementation with the macular carotenoids on MP, vision, and cognitive function in patients with AD versus controls. Methods: A randomized, double-blind clinical trial with placebo and active arms. 31 AD patients and […]
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation
Nathan, Pradeep J.,
Boardley, Rebecca,
Scott, Nicola,
Berges, Alienor,
Maruff, Paul,
Sivananthan, Tharani,
Upton, Neil,
Lowy, Martin T.,
Nestor, Peter J.,
Lai, Robert
Background: The histamine H3 receptor plays a critical role in the negative neuromodulation of neurotransmitters involved in cognitive function. H3 receptor antagonists/inverse agonists have been shown to exert pro-cognitive effects in pre-clinical models. GSK239512 is a potent and selective H₃ receptor antagonist developed for the treatment of cognitive dysfunction in neurodegenerative disorders. In this study […]
Efficacy of musical interventions in dementia: evidence from a randomized controlled trial
Narme, Pauline,
Clément, Sylvain,
Ehrlé, Nathalie,
Schiaratura, Loris,
Vachez, Sylvie,
Courtaigne, Bruno,
Munsch, Frédéric,
Samson, Séverine
Although musical interventions have recently gained popularity as a non-pharmacological treatment in dementia, there is still insufficient evidence of their effectiveness. To investigate this issue, a single-center randomized controlled trial was conducted with forty-eight patients with Alzheimer’s disease or mixed dementia to compare the effects of music versus cooking interventions in the emotional, cognitive, and […]
Cognitive-motor intervention in Alzheimer’s disease: Long-term results from the Maria Wolff trial
Mũniza, Ruben,
Serraa, Cristina Massegú,
Reisberga, Barry,
Rojo, José Manuel,
del Ser, Teodoro,
Casanova, Jordi Pẽna,
Olazarán, Javier
Background: Little is known about the long-term acceptance and effects of cognitive and motor stimulation interventions (CMSI) in Alzheimer’s disease (AD). Objective: To evaluate a replicable CMSI program for mild cognitive impairment (MCI) and mild-to-moderate AD persons. Methods: Eighty-four non-institutionalized subjects with AD were randomized to receive either CMSI, administered by a single care provider, […]